- Home
- DAWN vs CSTL Comparison
DAWN vs CSTL Comparison
Compare DAWN & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- CSTL
- Stock Information
- Founded
- DAWN 2018
- CSTL 2007
- Country
- DAWN United States
- CSTL United States
- Employees
- DAWN N/A
- CSTL N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- DAWN Health Care
- CSTL Health Care
- Exchange
- DAWN Nasdaq
- CSTL Nasdaq
- Market Cap
- DAWN 624.8M
- CSTL 697.9M
- IPO Year
- DAWN 2021
- CSTL 2019
- Fundamental
- Price
- DAWN $7.19
- CSTL $22.35
- Analyst Decision
- DAWN Strong Buy
- CSTL Strong Buy
- Analyst Count
- DAWN 7
- CSTL 6
- Target Price
- DAWN $27.86
- CSTL $37.67
- AVG Volume (30 Days)
- DAWN 1.1M
- CSTL 461.9K
- Earning Date
- DAWN 10-29-2025
- CSTL 11-03-2025
- Dividend Yield
- DAWN N/A
- CSTL N/A
- EPS Growth
- DAWN N/A
- CSTL N/A
- EPS
- DAWN N/A
- CSTL N/A
- Revenue
- DAWN $187,638,000.00
- CSTL $346,269,000.00
- Revenue This Year
- DAWN $12.56
- CSTL N/A
- Revenue Next Year
- DAWN $48.02
- CSTL N/A
- P/E Ratio
- DAWN N/A
- CSTL N/A
- Revenue Growth
- DAWN 2190.50
- CSTL 20.40
- 52 Week Low
- DAWN $5.64
- CSTL $14.59
- 52 Week High
- DAWN $16.76
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- CSTL 54.82
- Support Level
- DAWN $7.18
- CSTL $22.54
- Resistance Level
- DAWN $7.58
- CSTL $24.74
- Average True Range (ATR)
- DAWN 0.27
- CSTL 1.07
- MACD
- DAWN -0.03
- CSTL -0.13
- Stochastic Oscillator
- DAWN 33.92
- CSTL 46.47
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.